&nbsp;

GOC- SuggestedLanguageChallengingQuestions.pdf

Oct 2021

Document

GOC- SuggestedLanguageChallengingQuestions-FR.pdf

Oct 2021

Document

GOC- SuggestedLanguageChallengingQuestions-FR.pdf

Oct 2021

Document

GoalsOfCarePoster.pdf

Oct 2021

Document

GoalsOfCarePoster-FR.pdf

Oct 2021

Document

GOC-DocumentationTemplate-FR.pdf

Oct 2021

Document

GOC-DocumentationTemplate.pdf

Oct 2021

Regimen

LARO

Cancer Type:

Breast,

Central Nervous System,

Endocrine,

Adrenal,

Neuroendocrine,

Pancreatic Neuroendocrine,

Parathyroid,

Thymoma,

Thyroid,

Gastrointestinal,

Anus,

Colorectal,

Esophagus,

Gastric / Stomach,

Gastrointestinal Stromal Tumours,

Hepatobiliary / Liver / Bile Duct,

Mesothelioma (Peritoneal),

Neuroendocrine (GI),

Pancreas,

Rectal,

Small bowel and appendix,

Genitourinary,

Bladder / Urothelial,

Penile,

Prostate,

Renal cell / Kidney,

Testis,

Gynecologic,

Cervix,

Endometrial,

Germ Cell,

Gestational Trophoblastic Disease,

Ovary,

Uterine Sarcoma,

Vagina,

Vulva,

Head and Neck,

Larynx,

Nasopharynx,

Oral,

Paranasal Sinus,

Pharynx,

Salivary Gland,

Squamous Cell,

Kaposi's Sarcoma,

Lung,

Mesothelioma (Pleural),

Neuroendocrine (Lung),

Non-Small Cell,

Small Cell,

Sarcoma,

Desmoid Tumour,

Ewing's,

Ewing's and Soft Tissue,

GIST,

Giant Cell Tumour,

Kaposi's Sarcoma,

Osteogenic / Bone,

Soft Tissue,

Uterine,

Wilm's Tumour,

Skin,

Basal Cell,

Melanoma,

Merkel Cell,

Squamous Cell,

Unknown Primary

Intent: Palliative

Funding:

Exceptional Access Program

larotrectinib - For the treatment of unresectable locally advanced, or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion, according to clinical criteria

, Collapse Show fewer tags

Drugs Used:

larotrectinib

... Show more tags

Quick Link(s):

Regimen Monograph

Sep 2025

Document

LungCancerSxPathwayMap.pdf

Nov 2021

Drug

gemtuzumab ozogamicin

Other Name(s): Mylotarg®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Dec 1969

Regimen

GILT

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Palliative

Funding:

Exceptional Access Program

gilteritinib - Relapsed or Refractory FLT3-mutated acute myeloid leukemia